報價延遲最少15分鐘:2025/07/20 19:55 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
65.13 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.49/-3.28
|
|
企業價值
4.96B
|
| 資產負債 |
|
每股賬面淨值
21.18
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
35.00M
|
|
每股收益
1.97
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 19:55 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
